[1]赵 维,廖荣宏,王爱华.糖皮质激素治疗心力衰竭疗效与安全性的Meta分析[J].医学信息,2018,(14):70-74.[doi:10.3969/j.issn.1006-1959.2018.14.021]
 ZHAO Wei,LIAO Rong-hong,WANG Ai-hua.Meta-analysis of the Efficacy and Safety of Glucocorticoids in the Treatment of Heart Failure[J].Medical Information,2018,(14):70-74.[doi:10.3969/j.issn.1006-1959.2018.14.021]
点击复制

糖皮质激素治疗心力衰竭疗效与安全性的Meta分析()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2018年14期
页码:
70-74
栏目:
论著
出版日期:
2018-07-15

文章信息/Info

Title:
Meta-analysis of the Efficacy and Safety of Glucocorticoids in the Treatment of Heart Failure
文章编号:
1006-1959(2018)14-070-05
作者:
赵 维廖荣宏王爱华
重庆医科大学附属永川医院心血管内科,重庆 402160
Author(s):
ZHAO WeiLIAO Rong-hongWANG Ai-hua
Department of Cardiology,Yongchuan Hospital,Chongqing Medical University,Chongqing 402160,China
关键词:
糖皮质激素心力衰竭Meta分析
Keywords:
Key words:GlucocorticoidsHeart failureMeta-analysis
分类号:
R541.6
DOI:
10.3969/j.issn.1006-1959.2018.14.021
文献标志码:
A
摘要:
目的 评估糖皮质激素治疗心力衰竭的有效性及安全性。方法 计算机检索PubMed、Cochrane Library、OVID、MEDLINE、EMBASE、CNKI、VIP、万方等数据库,检索时间至2017年11月,纳入常规治疗+糖皮质激素(激素组)对比常规治疗(对照组)治疗心力衰竭的随机对照试验(RCT),统计数据采用RevMan5.3软件进行Meta分析。结果 该研究共纳入11个RCT,患者601例,Meta分析结果显示:激素组能降低患者全因死亡率[OR:0.20,95%CI(0.08,0.51),P=0.0009],改善心功能[OR:6.19,95%CI(3.22,9.51),P<0.0001]及肾功能[WMD:-16.94,95%CI(-29.47,-4.41),P=0.008],增加尿量[WMD:1253.62,95%CI(788.26,1718.99),P<0.0001]与对照组比较,差异具有统计学意义,两组患者不良反应发生率[OR:0.65,95%CI(0.34,1.25),P=0.20]比较,差异无统计学意义。结论 糖皮质激素可能作为辅助治疗心力衰竭的有效手段。
Abstract:
Abstract:Objective To evaluate the efficacy and safety of glucocorticoids in the treatment of heart failure.Methods The computer was searched for PubMed,Cochrane Library,OVID,MEDLINE,EMBASE,CNKI,VIP,Wanfang and other databases.The search time was from November 2017,and it was included in the routine treatment+glucocorticoid(hormone group)compared with conventional treatment (control group).Randomized controlled trial(RCT)of heart failure,statistical analysis using RevMan5.3 software for meta-analysis. Results The study included 11 RCTs with 601 patients.Meta-analysis showed that the hormone group reduced all-cause mortality in patients [OR:0.20,95% CI(0.08, 0.51),P=0.0009],improving cardiac function[OR:6.19,95% CI(3.22,9.51),P<0.0001]and renal function [WMD:-16.94,95% CI(-29.47,-4.41),P=0.008],increased urine output[WMD:1253.62,95 %CI(788.26,1718.99),P<0.0001]compared with the control group,the difference was statistically significant.The incidence of adverse reactions in the two groups[OR:0.65,95% CI (0.34,1.25),P=0.20],the difference was not statistically significant.Conclusion Glucocorticoid may be an effective means of adjuvant treatment of heart failure.

参考文献/References:

[1]Mosterd A,Hoes AW.Clinical epidemiology of heart failure[J].Heart,2007,93(9):1137-1146. [2]Dec GW.Management of Acute Decompensated Heart Failure[J].Current Problems in Cardiology,2007,32(6):321-366. [3]Massari F,Mastropasqua F,Iacoviello M,et al.The glucocorticoid in acute decompensated heart failure:Dr Jekyll or Mr Hyde[J].The American Journal of Emergency Medicine,2012,30(3):517. [4]中华医学会心血管病学分会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):3-10. [5]Liu C,Liu K.Cardiac Outcome Prevention Effectiveness of Glucocorticoids in Acute Decompensated Heart Failure COPE-ADHF Study[J].J Cardiovasc Pharmacol,2014,63(4):333-338. [6]Meng H,Liu G,Zhai J,et al.Prednisone in Uric Acid Lowering in Symptomatic Heart Failure Patients with Hyperuricemia-The PUSH-PATH3 Study[J].J Rheumatol,2015,42(5):866-869. [7]Zhang H,Liu C,Ji Z,et al.Prednisone adding to usual care treatment for refractory decompensated congestive heart failure[J].Int Heart J,2008,49(5):587-595. [8]魏新考,李亚昭,崔利锋.糖皮质激素辅助治疗对重症心力衰竭患者心功能及血浆皮质醇、脑钠肽的影响[J].医学综述,2017,23(3):581-584. [9]黎辉.厄贝沙坦氢氯噻嗪联合糖皮质激素治疗重症心力衰竭患者临床疗效的研究[J].中国急救医学,2016,36(2):130-133. [10]徐利,尹志超.泼尼松片治疗重症心力衰竭的临床疗效及其对神经内分泌因子的影响[J].实用心脑肺血管病杂志,2014,22(10):44-45. [11]何文平.小剂量糖皮质激素治疗顽固性心力衰竭30例疗效观察[J].现代医药卫生,2010,26(10):1533-1534. [12]陈华.强的松对心力衰竭治疗中利尿剂的利尿效果的影响的研究[D].河北医科大学,2007. [13]熊德高,岑本莲,石建.泼尼松治疗难治性心力衰竭33例[J].中国药业,2005,14(7):77-78. [14]李尚俭,陈新义.糖皮质激素辅助治疗慢性心力衰竭的疗效及其对神经体液因子影响的研究[J].实用医学杂志,2005,21(9):964-966. [15]卢亮,厉伟民.肾上腺皮质功能变化在顽固性充血性心力衰竭患者中的临床意义[J].中国危重病急救医学,2003,15(8):489-491. [16]Aguirre JA,Ibarra FR,Barontini M,et al.Effect of glucocorticoids on renal dopamine production[J].Eur J Pharmacol,1999,370(3):271-278. [17]Liu C,Chen Y,Kang Y,et al.Glucocorticoids improve renal responsiveness to atrial natriuretic peptide by up-regulating natriuretic peptide receptor-A expression in the renal inner medullary collecting duct in decompensated heart failure[J].J Pharmacol Exp Ther,2011,339(1):203-209. [18]甄宇治,邓彦东,刘超,等.糖皮质激素对重症心力衰竭患者神经内分泌因子影响的临床研究[J].中国全科医学,2012,15(1):54-56. [19]De Matteo R,May CN.Glucocorticoid-induced renal vasodilatation is mediated by a direct renal action involving nitric oxide[J].Am J Physiol,1997,273(6):R1972-R1979.

相似文献/References:

[1]郭俊林,张立.BNP对CRT后期疗效的临床评价[J].医学信息,2018,(01):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
 GUO Jun-lin,ZHANG li.Clinical Evaluation of BNP in Treatment of Late CRT[J].Medical Information,2018,(14):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
[2]钟时嘉.亚急性甲状腺炎的临床分析[J].医学信息,2018,(01):181.[doi:10.3969/j.issn.1006-1959.2018.01.073]
 ZHONG Shi-jia.Clinical Analysis of Subacute Thyroiditis[J].Medical Information,2018,(14):181.[doi:10.3969/j.issn.1006-1959.2018.01.073]
[3]唐培渊,宋俊峰,秦克乐,等.难治性特发性血小板减少性紫癜的治疗进展[J].医学信息,2018,(05):42.[doi:10.3969/j.issn.1006-1959.2018.05.016]
 TANG Pei-yuan,SONG Jun-feng,QIN Ke-le,et al.Progress in Treatment of Refractory Idiopathic Thrombocytopenic Purpura[J].Medical Information,2018,(14):42.[doi:10.3969/j.issn.1006-1959.2018.05.016]
[4]苗艳茹.甲巯咪唑与糖皮质激素联合治疗甲状腺功能亢进症合并症的效果分析[J].医学信息,2018,(05):136.[doi:10.3969/j.issn.1006-1959.2018.05.048]
 MIAO Yan-ru.Analysis of Effects of Methimazole and Glucocorticoids on Complications of Hyperthyroidism[J].Medical Information,2018,(14):136.[doi:10.3969/j.issn.1006-1959.2018.05.048]
[5]康 凯,郑继伟,王 闰.糖皮质激素治疗甲亢伴浸润性突眼的疗效分析[J].医学信息,2018,(08):103.[doi:10.3969/j.issn.1006-1959.2018.08.033]
 KANG Kai,ZHENG Ji-wei,WANG Run.Efficacy of Glucocorticoids in the Treatment of Hyperthyroidism with Infiltrating Exophthalmos[J].Medical Information,2018,(14):103.[doi:10.3969/j.issn.1006-1959.2018.08.033]
[6]程 林.重组人脑利钠肽用于重症急性心肌炎伴 心力衰竭患者治疗的临床研究[J].医学信息,2018,(08):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
 CHENG Lin.Clinical Study of Recombinant Human Brain Natriuretic Peptide in the Treatment of Patients with Severe Acute Myocarditis and Heart Failure[J].Medical Information,2018,(14):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
[7]胡丽君.螺内酯联合曲美他嗪治疗慢性心力衰竭的疗效分析[J].医学信息,2018,(08):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
 HU Li-jun.Efficacy of Spironolactone Combined with Trimetazidine in the Treatment of Chronic Heart Failure[J].Medical Information,2018,(14):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
[8]李 铎,王建华.盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响[J].医学信息,2018,(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
 LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Medical Information,2018,(14):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
[9]何玲玲,程淑芬.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭疗效观察[J].医学信息,2018,(13):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
 HE Ling-ling,CHENG Shu-fen.Therapeutic Effect of Trimetazidine Combined with Metoprolol Succinate in the Treatment of Coronary Heart Disease with Heart Failure[J].Medical Information,2018,(14):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
[10]施国富,吴春阳,施亚明,等.血浆脑钠肽对射血分数保留心力衰竭患者的诊断价值研究[J].医学信息,2018,(16):47.[doi:10.3969/j.issn.1006-1959.2018.16.013]
 SHI Guo-fu,WU Chun-yang,SHI Ya-ming,et al.Diagnostic Value of Plasma Brain Natriuretic Peptide in Patients with Heart Failure Preserved by Ejection Fraction[J].Medical Information,2018,(14):47.[doi:10.3969/j.issn.1006-1959.2018.16.013]

更新日期/Last Update: 2018-07-15